Maintenance and cure of the L5178Y murine tumor-dormant state by interleukin 2: dependence of interleukin 2 on induced interferon-gamma and on tumor necrosis factor for its antitumor effects.
We reported previously that treatment of peritoneal cell (PC) cultures prepared from mice which harbor L5178Y lymphoma cells in a tumor-dormant state in their peritoneal cavity with interleukin 2 (HuIL-2) stimulated antitumor cytotoxic activity in both the nonadherent and adherent populations derived from such cultures. We report here that HuIL-2 induced the production of murine gamma interferon (MuIFN-gamma) in these PC cultures and required Lyt-1-, Lyt-2-, and L3T4-expressing lymphocytes to do so. HuIL-2 required and synergized with this induced MuIFN-gamma to stimulate cytotoxic activity in the nonadherent PC and the MuIFN-gamma itself stimulated cytotoxic activity in the adherent PC. Cyclosporin A prevented both the induction of MuIFN-gamma and the development of antitumor cytotoxic activity in HuIL-2-treated PC cultures. An addback of exogenous MuIFN-gamma to HuIL-2-cyclosporin A-treated PC cultures and to the nonadherent subpopulation of such cultures, at a concentration which itself produced no antitumor effect, permitted HuIL-2 to induce its antitumor effect. We previously reported that MuIFN-gamma requires the action of murine tumor necrosis factor (MuTNF) to induce cytotoxic activity in PC cultures from tumor-dormant mice. We report here that HuIL-2 also requires the action of (MuTNF) to stimulate antitumor cytotoxic activity in PC cultures from tumor-dormant mice. These results indicate that HuIL-2 induces MuIFN-gamma and requires and synergizes with this MuIFN-gamma and with (MuTNF) to stimulate antitumor cytotoxic activity in PC cultures from tumor-dormant mice.
Chen
L P
LP
Department of Pathology, Hahnemann University, Philadelphia, Pennsylvania 19102.
Suzuki
Y
Y
Liu
C M
CM
Wheelock
E F
EF
D000818:Animals; D004357:Drug Synergism; D005260:Female; D007371:Interferon-gamma / Q000096:biosynthesis* / Q000276:immunology; D007376:Interleukin-2 / Q000494:pharmacology*; D007940:Leukemia L5178 / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D007942:Leukemia, Experimental / Q000188:drug therapy*; D008222:Lymphokines / Q000494:pharmacology; D016215:Macrophage-Activating Factors; D051379:Mice; D008811:Mice, Inbred DBA; D010529:Peritoneal Cavity / Q000166:cytology; D013601:T-Lymphocytes / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis* / Q000276:immunology
D007376:Interleukin-2; D008222:Lymphokines; D016215:Macrophage-Activating Factors; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma